A detailed history of Qube Research & Technologies LTD transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 129,191 shares of PCRX stock, worth $1.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
129,191
Holding current value
$1.9 Million
% of portfolio
0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$25.5 - $31.51 $3.29 Million - $4.07 Million
129,191 New
129,191 $3.7 Million
Q3 2023

Nov 13, 2023

BUY
$30.68 - $40.09 $546,318 - $713,882
17,807 New
17,807 $546,000
Q1 2023

May 15, 2023

SELL
$35.53 - $43.38 $557,607 - $680,805
-15,694 Reduced 29.78%
37,010 $1.51 Million
Q4 2022

Feb 14, 2023

BUY
$38.19 - $57.45 $2.01 Million - $3.03 Million
52,704 New
52,704 $2.03 Million
Q2 2022

Aug 15, 2022

BUY
$51.49 - $81.64 $1.22 Million - $1.94 Million
23,754 New
23,754 $1.39 Million
Q1 2022

May 09, 2022

SELL
$60.03 - $76.49 $468,113 - $596,469
-7,798 Closed
0 $0
Q4 2021

Feb 01, 2022

SELL
$47.97 - $62.21 $36,840 - $47,777
-768 Reduced 8.97%
7,798 $469,000
Q3 2021

Nov 12, 2021

SELL
$54.64 - $61.3 $1,748 - $1,961
-32 Reduced 0.37%
8,566 $480,000
Q2 2021

Aug 13, 2021

BUY
$59.18 - $69.99 $227,961 - $269,601
3,852 Added 81.16%
8,598 $522,000
Q1 2021

May 14, 2021

BUY
$59.31 - $78.82 $281,485 - $374,079
4,746 New
4,746 $333,000
Q3 2020

Nov 12, 2020

SELL
$51.97 - $63.0 $744,678 - $902,727
-14,329 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$30.8 - $52.47 $441,333 - $751,842
14,329 New
14,329 $752,000
Q1 2020

May 15, 2020

SELL
$28.4 - $50.7 $380,616 - $679,481
-13,402 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$36.31 - $46.83 $486,626 - $627,615
13,402 New
13,402 $607,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $673M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.